The ROCK® (Redirected Optimized Cell Killing) platform allows for a modular approach to generating customizable ICE® (innate cell engager) molecules. High-affinity ICE® (innate cell engager) molecules, which are created using the ROCK® platform, are capable of bivalent NK-cell binding via CD16A without inducing nonspecific NK-cell activation or cell fratricide. The bivalent interaction of our ICE® (innate cell engager) molecules with CD16A increases NK-cell activation and antitumor activity. ICE® (innate cell engager) molecules with a tetravalent, bispecific structure may stimulate increased tumor-cell killing in vitro relative to Fc-enhanced IgG antibodies.
*Based on AFM13 clinical studies.
Tailoring tetravalent, bispecific ICE® (innate cell engager) molecules to specific indications.
Proven record in building potent and stable ICE® (innate cell engager) molecules.
Allows for specific CD16A-targeting.
publications and posters
See our wealth of clinical literature (2009-2021).
Explore our growing pipeline of ICE® (innate cell engager) molecules and combination products.
Join the next revolution in cancer treatment.
ADCC=antibody-dependent cellular cytotoxicity; CD=cluster of differentiation; Fc=fragment crystallizable; IgG=immunoglobulin G; NK=natural killer.
Reference: Ellwanger K, Reusch U, Fucek I, et al. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. MAbs. 2019;11(5):899-918.